# Reimagining Longevity: DR. ADEEL KHAN on Muse Cells & the Future of Regenerative Medicine

Page: https://stenobird.com/podcast/tech-innovation-and-society/reimagining-longevity-dr-adeel-khan-on-muse-cells-the-future-of-regenerative-medicine
Text version: https://stenobird.com/podcast/tech-innovation-and-society/reimagining-longevity-dr-adeel-khan-on-muse-cells-the-future-of-regenerative-medicine.md
Podcast: [Tech, Innovation & Society - The Creative Process: Technology, AI, Software, Future, Economy, Science, Engineering & Robotics Interviews](https://stenobird.com/podcast/tech-innovation-and-society)
Published: 2026-01-23T11:57:00+00:00
Episode link: https://www.creativeprocess.info/technology-innovation-society/adeel-khan
Audio file: https://static1.squarespace.com/static/5745d9f137013b9d0a627c60/t/697605baf8f9c07d0716ed5e/1769342449354/adeel-khan-the-creative-process-podcast-FULL.mp3
Processing state: processed
JSON: https://stenobird.com/v1/public/podcasts/tech-innovation-and-society/episodes/reimagining-longevity-dr-adeel-khan-on-muse-cells-the-future-of-regenerative-medicine
Duration seconds: 2892

## Resource

Dr. Adeel Khan explains how MUSE cells offer a safer, pluripotent alternative to traditional stem cell therapies for true tissue regeneration. The discussion explores the transition from managing chronic symptoms to actively reversing disease through advanced regenerative medicine.

## Highlights
- Main idea: MUSE cells are pluripotent and capable of creating new tissue, unlike standard MSCs which primarily reduce inflammation
- Practical takeaway: True regenerative therapy requires standardized cell populations rather than simple umbilical cord injections
- Failure mode: Many clinics market 'stem cell' procedures that are actually just anti-inflammatory injections, failing to provide actual repair
- Future outlook: The integration of stem cells, gene therapy, and fecal microbial transplants could cure autoimmune diseases within a decade
- Safety note: MUSE cells provide pluripotency without the cancer risks associated with traditional Yamanaka factor reprogramming

## Topics

Regenerative Medicine, MUSE Cells, Stem Cell Therapy, Longevity, Biotechnology, Pluripotency, Autoimmune Disease, Tissue Engineering

## Chapters
- 1:00 — The Shift in Regenerative Medicine: Dr. Khan introduces the transition from symptom management to active tissue repair using advanced cell therapies.
- 4:40 — Standardizing Cell Populations: The technical challenges of isolating specific, high-quality cell populations for consistent therapeutic results.
- 8:20 — Limitations of Current Treatments: A comparison between traditional cortisone and PRP injections versus true regenerative cell therapy.
- 12:00 — The Democratization of Innovation: How advanced medical technologies move from elite accessibility to the broader public through economies of scale.
- 15:40 — Frequency and Biological Impact: Discussing the importance of dosing frequency and the biological response to cell-based interventions.
- 19:10 — Clinical Trials and FDA Pathways: The progress of phase trials for heart attack recovery and the regulatory roadmap for US approval.
- 22:50 — Navigating the Regulatory Landscape: Warning against unregulated clinics and the importance of informed decision-making in stem cell procedures.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/tech-innovation-and-society/episodes/reimagining-longevity-dr-adeel-khan-on-muse-cells-the-future-of-regenerative-medicine/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/tech-innovation-and-society/reimagining-longevity-dr-adeel-khan-on-muse-cells-the-future-of-regenerative-medicine.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.